Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 10mg - film coated tablet - 10 mg - active: simvastatin 10mg excipient: ascorbic acid butylated hydroxyanisole carnauba wax citric acid monohydrate hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 20mg - film coated tablet - 20 mg - active: simvastatin 20mg excipient: ascorbic acid butylated hydroxyanisole carnauba wax citric acid monohydrate hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 40mg - film coated tablet - 40 mg - active: simvastatin 40mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 5mg - film coated tablet - 5 mg - active: simvastatin 5mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 80mg - film coated tablet - 80 mg - active: simvastatin 80mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide red lactose monohydrate magnesium stearate methylated spirits microcrystalline cellulose purified talc purified water   starch titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

air liquide new zealand ltd - argon 1%; nitrogen 78%; oxygen 21% - gas - active: argon 1% nitrogen 78% oxygen 21%

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

air liquide new zealand ltd - nitrous oxide 100% (>98% purity);  ;   - gas - 98 % - active: nitrous oxide 100% (>98% purity)    

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

air liquide new zealand ltd - oxygen 99.5%;  ;   - gas - 99.5 % - active: oxygen 99.5%    

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fisher & paykel healthcare pty ltd - 61365 - medical gas flowmeter, thorpe tube - to supply medical co2 gas from high pressure co2 cylinders to a lower, regulated pressure suitable for use in surgical procedures requiring co2 gas.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

fisher & paykel healthcare pty ltd - 47487 - medical device electrical cable, general purpose - intended for transferring data between computers and medical devices.